BioClinica, Inc. has acquired Synowledge, expanding its services into the drug safety and regulatory outsourcing market. Synowledge specializes in pharmacovigilance, regulatory affairs and information technology services to support biopharma companies with recording, analyzing and reporting adverse drug events. Synowledge is headquartered in Miami, FL and employs a global workforce of more than 500.
 
“This acquisition extends BioClinica’s solutions into an important new area for our customers,” said BioClinica president and chief executive officer John Hubbard. “Synowledge is a highly regarded provider that biopharmaceutical corporations trust to manage the critical process of monitoring and reporting adverse drug events.  It’s the capabilities complement our deep scientific expertise and technology-enabled services that support our customers in developing and bringing new drugs to market as safely and efficiently as possible.”
 
Sankesh Abbhi, who founded Synowledge, said, “We are very pleased to become part of BioClinica. Our companies share a deep commitment to serving our customers and supporting their goals through highly specialized expertise and tailored solutions. Together, we offer customers a broader set of services and increased access to resources that support their overall drug development process.”
 
Mr. Abbhi will serve as senior vice president and head of global safety and regulatory solutions, reporting to Mukhtar Ahmed, president of BioClinica’s eClinical Solutions Division.